Zantac, a popular heartburn medication, has become the focus of mass tort litigation due to claims that it causes serious health issues, including various forms of cancer such as bladder, stomach, and esophageal cancer. Plaintiffs in these lawsuits, who have used Zantac for extended periods, allege that manufacturers like Sanofi and GlaxoSmithKline failed to warn consumers about the potential risks associated with the presence of N-Nitrosodimethylamine (NDMA), a known carcinogen, in the medication. The litigation has drawn attention to the need for safer pharmaceutical products and more rigorous testing and regulation of medications. Significant settlements and verdicts have been awarded, and ongoing legal actions continue to highlight the public health implications. Regulatory agencies and advocacy groups are pushing for stricter safety standards, clearer labeling, and increased research into the long-term effects of NDMA exposure in medications like Zantac. The goal of these legal efforts is to secure compensation for affected individuals and ensure safer consumer products in the pharmaceutical industry.